Table 1.
Data from pegylated interferon plus ribavirin arms from four pivotal studies examining the treatment of chronic hepatitis C virus infection in HIV-infected individuals.
| Characteristic | ACTG 5071 (N=133) |
APRICOT (N=868) |
RIBAVIC (N=412) |
PRESCO (N=389) |
|---|---|---|---|---|
| Site | U.S. | U.S., Europe, Australia | France | Spain |
| Peginterferon formulation | Peginterferon α-2a | Peginterferon α-2a | Peginterferon α-2b | Peginterferon α-2a |
| Ribavirin dose | 600 mg/d – 1000 mg/d | 800 mg/d | 800 mg/d | 1000 mg/d – 1200 mg/d |
| HCV genotype 1 (%) | 77 | 61 | 48 | 51 |
| Bridging fibrosis/cirrhosis (%) | 11 | 12 | 39 | 27 |
| On antiretroviral therapy (%) | 85 | 84 | 83 | 67% |
| CD4 cell count (/mm3) | 453 (median) | 520 (mean) | 547 (median) | 540 (mean) |
| Undetectable HIV RNA (%) | 61 (<50 copies/mL) |
60 (<50 copies/mL) |
70 (<400 copies/mL) |
NR |
| SVR rate, genotype 1 (%) | 14 | 29 | 17 | 35 |
| SVR rate, genotype 2/3 (%) | 73 | 62 | 44 | 72 |
| Withdrawal rate (%) | 12 | 25 | 39 | 45 |
HIV=human immunodeficiency virus; SVR=sustained virologic response; NR=not reported